Establishing biomarkers for soft tissue sarcomas.
Expert Rev Anticancer Ther
; 24(6): 407-421, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38682679
ABSTRACT
INTRODUCTION:
Soft tissue sarcomas (STS) are a rare and diverse group of tumors. Curative options are limited to localized disease, with surgery being the mainstay. Advanced stages are associated with a poor prognosis. Currently, the prognosis of the patient is based on histological classification and clinical characteristics, with only a few biomarkers having entered clinical practice. AREAS COVERED This article covers extensive recent research that has established novel potential biomarkers based on genomics, proteomics, and clinical characteristics. Validating and incorporating these biomarkers into clinical practice can improve prognosis, prediction of recurrence, and treatment response. Relevant literature was collected from PubMed, Scopus, and clinicaltrials.gov databases (November 2023). EXPERT OPINION Currently, defining prognostic markers in soft tissue sarcomas remains challenging. More studies are required, especially to personalize treatment through advanced genetic profiling and analysis using individual tumor and patient characteristics.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Sarcoma
/
Biomarcadores Tumorais
/
Genômica
/
Proteômica
Limite:
Humans
Idioma:
En
Revista:
Expert Rev Anticancer Ther
Ano de publicação:
2024
Tipo de documento:
Article